Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma : results from the MRC (UK) V Trial

Tools
- Tools
+ Tools

Brown, R. D., Joshua, D. E., Nelson, M., Gibson, J., Dunn, Janet A. and MacLennan, I. C. M. (1993) Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma : results from the MRC (UK) V Trial. British Journal of Haematology, 84 (2). pp. 238-241. doi:10.1111/j.1365-2141.1993.tb03058.x

Research output not available from this repository, contact author.
Official URL: https://doi.org/10.1111/j.1365-2141.1993.tb03058.x

Request Changes to record.

Abstract

The significance of serum thymidine kinase (STK) as a prognostic indicator for patients with myeloma has been evaluated by determining the pre‐treatment level of STK in a retrospective study of 547 patients from the Medical Research Council (MRC) V Myeloma Trial. Overall, STK was a highly significant prognostic factor (Chi2= 7.91; P= 0.005). At the time of censor, 23.4% of patients with a presentation STK of < 6 U/l but only 7.9% of the patients with an STK of > 11 U/l were still alive. STK proved to be a highly significant prognostic indicator for the 270 melphalan‐treated patients (Chi2= 12·37; P, = 0.0004) but had no prognostic significance for the 277 ABCM (adriamycin, BCNU, cyclophosphamide and melphalan) treated patients (Chi2= 0.29; P= 0.59). When the STK data was stratified for serum B‐2‐microglobulin (SB2M) it was demonstrated that STK was independent of SB2M and provided additional prognostic information for patients who were treated with melphalan. Thus patients with both a low STK and SB2M had the best prognosis (median survival 1677 d) and those patients with a high STK and SB2M had the worst prognosis (median survival 519 d). STK is a good prognostic marker for patients treated with melphalan but the prognostic significance of STK may disappear with the introduction of new chemotherapy regimens.

Item Type: Journal Article
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit
Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
Journal or Publication Title: British Journal of Haematology
Publisher: Wiley-Blackwell Publishing Ltd.
ISSN: 0007-1048
Official Date: 1 June 1993
Dates:
DateEvent
1 June 1993Published
30 December 1992Accepted
2 October 1992Submitted
Volume: 84
Number: 2
Page Range: pp. 238-241
DOI: 10.1111/j.1365-2141.1993.tb03058.x
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us